{"id":2005,"date":"2026-03-12T11:05:00","date_gmt":"2026-03-12T11:05:00","guid":{"rendered":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/?page_id=2005"},"modified":"2026-03-12T11:42:56","modified_gmt":"2026-03-12T11:42:56","slug":"mindset-2","status":"publish","type":"page","link":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/mindset-2\/","title":{"rendered":"MINDSET 2"},"content":{"rendered":"\n
<\/div>
<\/div><\/div>
\n

MINDSET 2: A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer\u2019s Disease<\/h2>\n<\/div><\/div><\/div><\/div><\/div>\n\n\n\n
\n
\"BMS\"<\/figure>
\n

Project Details<\/strong><\/p>\n\n\n\n

Start Date
2026<\/strong><\/p>\n\n\n\n

Status
Study in Setup<\/strong><\/p>\n\n\n\n

Principal Investigator
Dr Tom Russ<\/a><\/p>\n\n\n\n

NDN Study Lead
Bev Goldberg<\/a><\/p>\n\n\n\n

Main Research Site
Western General Hospital<\/strong><\/p>\n<\/div><\/div>\n\n\n\n

This clinical trial looks to see if the medications KarXT + KarX-EC improve memory and thinking problems in people with Alzheimer’s Disease.<\/strong><\/p>\n\n\n\n

What Happens In This Study?<\/strong><\/p>\n\n\n\n

You will either be given medicines called KarXT + KarX-EC <\/strong>or two placebos<\/strong> (dummy pills that looks like the medicine but have no active ingredients). Neither you, nor the research team, will know which group you are in.<\/p>\n\n\n\n

Can I Join This Study?<\/strong><\/p>\n\n\n\n

To take part in this medical trial, you must meet these 8 requirements<\/strong>:<\/p>\n\n\n\n

    \n
  1. Your Diagnosis:<\/strong> A doctor must have confirmed that you have Alzheimer’s disease<\/strong>.<\/li>\n\n\n\n
  2. Your Symptoms:<\/strong> Your Alzheimer’s symptoms should be mild or moderate<\/strong>. A doctor will be able to assess your symptom severity.<\/li>\n\n\n\n
  3. Your Age:<\/strong> You are between 60 and 85 years old<\/strong>.<\/li>\n\n\n\n
  4. Your Study Partner:<\/strong> You must have a reliable friend of family member<\/strong> who knows you well and you see regularly, who can also take part to provide us with information on how you are doing.<\/li>\n\n\n\n
  5. Your Current Medicine:<\/strong> If you are taking Alzheimer\u2019s disease medication, you must have been taking this for at least 3 months,<\/strong> without making any big changes to it.<\/li>\n\n\n\n
  6. Your Permission:<\/strong> You must be able to understand what happens in the study and sign a form (called informed consent<\/strong>) to say you agree to join.<\/li>\n\n\n\n
  7. Your Time:<\/strong> You must do your best to attend all your study visits, and follow the rules of the study until it ends.<\/li>\n\n\n\n
  8. Taking the Medicine:<\/strong> You must be willing and able to swallow the trial medication.<\/li>\n<\/ol>\n\n\n\n

    Study Length<\/strong>: 24 weeks (with an optional additional 24 weeks where you are guaranteed to be on the medication)<\/p>\n\n\n\n

    Number of appointments<\/strong>: 12 visits (with an optional additional 7 visits)<\/p>\n\n\n\n

    More information on the trial can be found on the BMS <\/a>website.<\/p>\n<\/div><\/div>\n\n\n\n